Fig 1: Aand B, Western blot and qRT-PCR assays were performed to determine ST6GALNAC5 expression in PC3 cells. C, Bioinformatics analysis revealed that ST6GALNAC5 was a direct target of miR-182. D, Luciferase reporter assay was performed in HEK 293T cells. Data are reported as means±SD. **P<0.001 (paired t-test). E, Pearson analysis indicated miR-182 level was negatively correlated with ST6GALNAC5 in prostate cancer tissues. WT: wild type; Mut: mutant; NC: negative control.
Fig 2: A, shRNA against ST6GALNAC5 or miR-182 was designed, and silence of both miR-182 and ST6GALNAC5 rescued cell proliferation, which was attenuated by miR-182 knockdown in PC3 and Du145. Knockdown of ST6GALNAC5 counteracted inhibition effects caused by miR-182 knockdown on colony formation (B) and invasion (C) capacities (scale bar 100 μm). Data are reported as means±SD. *P<0.05; **P<0.01 (one-way ANOVA). NC: negative control.
Fig 3: A, Expression of miR-182 in 25 pairs of prostate cancer (PCa) tissue and adjacent noncancerous tissue samples were analyzed by qRT-PCR. B and C, ST6GALNAC5 in tissues was also determined by qRT-PCR and western blot. D, Expressions of miR-182 and (E and F) ST6GALNAC5 in PCa cell lines were analyzed by qRT-PCR. Data are reported as means±SD. *P<0.05; **P<0.01 (paired t-test and one-way ANOVA).
Supplier Page from Abcam for Anti-ST6GALNAC5 antibody [MM0916-29G28]